Aa
Chloroquine with Anti-Viral Drugs
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
I know this is old, but it looks extremely interesting to me
I have been taking methylene blue and it has made me feel SO MUCH better it's unbelievable
Did anyone try the combination suggested here? If not I may do so
You can access the full text of the study here: https://rjptonline.org/HTMLPaper.aspx?Journal=Research%20Journal%20of%20Pharmacy%20and%20Technology;PID=2008-1-3-67
I have been taking methylene blue and it has made me feel SO MUCH better it's unbelievable
Did anyone try the combination suggested here? If not I may do so
You can access the full text of the study here: https://rjptonline.org/HTMLPaper.aspx?Journal=Research%20Journal%20of%20Pharmacy%20and%20Technology;PID=2008-1-3-67
Background: Studies using safe natural products {Blue green® tablet (Rhodiola rosea L. root dry extract; Eleutherococcus senticosus Maxim. root dry extract; Ginkgo biloba L. leaf dry extract; Klamath microalgae Aphanizomenon flos aquae (AFA) 50 mg)} showed its antiviral effect. As well as vitamin D3, linolenic acid, black seeds and honey. The aim of the study was to determine the efficacy of combination of these natural products and chloroquine in treatment of HCV patients refusing or unfit for combined Interferon and Ribavirin (INF/RBV) therapy or HCV patients who failed to achieve sustained virological response to INF/RBV.
Methods: Patients with detectable HCV RNA with different stages of fibrosis and cirrhosis refusing or unfit for combined Interferon Ribavirin (INF/RBV) therapy or patients who failed to achieve sustained virological response to INF/RBV from April 2009 to March 2012 were included in this study. All the patients were treated first from coinfection as schistosomiasis and helicobacter pylori if present then received combination Blue green® tablet-original natural company, Italy; 2 tablet/30 kg once daily; Vitamin D: 1000 IU/day; tablespoon filled with paste made of linolenic acid, black seeds powder and honey; and 250 mg chloroquine once daily for 10 days and then every 3 days through the duration of therapy.
Results: 195 patients with chronic HCV were included; mean age 47.8 ± 9.03 years, 67.7% males. All patients have chronic hepatitis. 24 patients had cirrhosis. 82 (42.1%) achieved negative HCV RNA after 6 months of treatment. After 12 months of treatment, 107 (54.9%) patients had negative HCV RNA. 125 (64.3%) patients achieved ETR after 18 months of treatment. Moreover, 4/6 (66.6%) patients with combined HCV and HBV showed undetectable HBV after 3 months. Two out of 8 (25%) patients who failed to achieve SVR with previous (INF/RBV) have ETR.
Conclusion: Combination of safe natural products (Blue green® tablet, vitamin D3, linolenic acid, black seeds and honey) and chloroquine may have a role to achieve SVR in combination with recent direct acting antiviral drugs for HCV infection.
Methods: Patients with detectable HCV RNA with different stages of fibrosis and cirrhosis refusing or unfit for combined Interferon Ribavirin (INF/RBV) therapy or patients who failed to achieve sustained virological response to INF/RBV from April 2009 to March 2012 were included in this study. All the patients were treated first from coinfection as schistosomiasis and helicobacter pylori if present then received combination Blue green® tablet-original natural company, Italy; 2 tablet/30 kg once daily; Vitamin D: 1000 IU/day; tablespoon filled with paste made of linolenic acid, black seeds powder and honey; and 250 mg chloroquine once daily for 10 days and then every 3 days through the duration of therapy.
Results: 195 patients with chronic HCV were included; mean age 47.8 ± 9.03 years, 67.7% males. All patients have chronic hepatitis. 24 patients had cirrhosis. 82 (42.1%) achieved negative HCV RNA after 6 months of treatment. After 12 months of treatment, 107 (54.9%) patients had negative HCV RNA. 125 (64.3%) patients achieved ETR after 18 months of treatment. Moreover, 4/6 (66.6%) patients with combined HCV and HBV showed undetectable HBV after 3 months. Two out of 8 (25%) patients who failed to achieve SVR with previous (INF/RBV) have ETR.
Conclusion: Combination of safe natural products (Blue green® tablet, vitamin D3, linolenic acid, black seeds and honey) and chloroquine may have a role to achieve SVR in combination with recent direct acting antiviral drugs for HCV infection.
http://books.google.com/books?id=RdZEAAAAQBAJ&pg=PA188&lpg=PA185&ots=C5JDFiDv4p&focus=viewport&dq=Artemisinin+hbv+treatment&output=html_text
http://books.google.com/books?id=RdZEAAAAQBAJ&pg=PA185&lpg=PA185&dq=Artemisinin+hbv+treatment&source=bl&ots=C5JDFiDv4p&sig=rTXsRXJ8B3G87W2e3iWDeK7-LkU&hl=en&sa=X&ei=qyeJU_78CYe9oQSRxoGwCA&ved=0CDgQ6AEwBg
http://store.alchemistlab.com/products/super-artemisinin
There is also artemisin natural compound. They know for a long time that antimalarya compounds also work against viruses. But nobody is looking into it. Reasons are obvious that we hammer on here often. Try artemisin flameboy and see what your labs show. There are some interesting articles on it.
There is also artemisin natural compound. They know for a long time that antimalarya compounds also work against viruses. But nobody is looking into it. Reasons are obvious that we hammer on here often. Try artemisin flameboy and see what your labs show. There are some interesting articles on it.
Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo
The presentation of exogenous protein antigens in a major histocompatibility complex class I–restricted fashion to CD8+ T cells is called cross-presentation. We demonstrate that cross-presentation of soluble viral antigens (derived from hepatitis C virus [HCV], hepatitis B virus [HBV], or human immunodeficiency virus) to specific CD8+ T cell clones is dramatically improved when antigen-presenting dendritic cells (DCs) are pulsed with the antigen in the presence of chloroquine or ammonium chloride, which reduce acidification of the endocytic system. The export of soluble antigen into the cytosol is considerably higher in chloroquine-treated than in untreated DCs, as detected by confocal microscopy of cultured cells and Western blot analysis comparing endocytic and cytosolic fractions. To pursue our findings in an in vivo setting, we boosted groups of HBV vaccine responder individuals with a further dose of hepatitis B envelope protein vaccine with or without a single dose of chloroquine. Although all individuals showed a boost in antibody titers to HBV, six of nine individuals who were administered chloroquine showed a substantial CD8+ T cell response to HBV antigen, whereas zero of eight without chloroquine lacked a CD8 response. Our results suggest that chloroquine treatment improves CD8 immunity during vaccination.
The presentation of exogenous protein antigens in a major histocompatibility complex class I–restricted fashion to CD8+ T cells is called cross-presentation. We demonstrate that cross-presentation of soluble viral antigens (derived from hepatitis C virus [HCV], hepatitis B virus [HBV], or human immunodeficiency virus) to specific CD8+ T cell clones is dramatically improved when antigen-presenting dendritic cells (DCs) are pulsed with the antigen in the presence of chloroquine or ammonium chloride, which reduce acidification of the endocytic system. The export of soluble antigen into the cytosol is considerably higher in chloroquine-treated than in untreated DCs, as detected by confocal microscopy of cultured cells and Western blot analysis comparing endocytic and cytosolic fractions. To pursue our findings in an in vivo setting, we boosted groups of HBV vaccine responder individuals with a further dose of hepatitis B envelope protein vaccine with or without a single dose of chloroquine. Although all individuals showed a boost in antibody titers to HBV, six of nine individuals who were administered chloroquine showed a substantial CD8+ T cell response to HBV antigen, whereas zero of eight without chloroquine lacked a CD8 response. Our results suggest that chloroquine treatment improves CD8 immunity during vaccination.
test often so you may pick up abnormal alt or hbvdna....
artensunate,nitazoxanide and simvastatin won t work but since cheap you may try and see
artensunate,nitazoxanide and simvastatin won t work but since cheap you may try and see
i cannot go for sequential treatment as no doctor will put me on any treatment..... lowhbvdna normal alt fibroscan 5.3....hbsag 10,000
unless i try and fund it myself. but then trying to get the meds in the uk is near impossible.
i even asked piero if a hbsag 10,000 could warrant peg treatment and he said absoulutley not, so im stuck.....
i may just try and combo artensunate,nitazoxanide and simvastatin because i can get those but then i dont think that is enuough.....
i dont remember the last time i went to the doctors and actually got healed for anything.
sick care not health care.
unless i try and fund it myself. but then trying to get the meds in the uk is near impossible.
i even asked piero if a hbsag 10,000 could warrant peg treatment and he said absoulutley not, so im stuck.....
i may just try and combo artensunate,nitazoxanide and simvastatin because i can get those but then i dont think that is enuough.....
i dont remember the last time i went to the doctors and actually got healed for anything.
sick care not health care.
i d just go for sequential and try ezetimibe, nitazoxanide or artesunate add on when using pegintf to increase its response and see
you may try to contact the doctors of the study and see if they clear this point.my guess is they mean response to chloroquine because it has a highrate of resistance
you may try to contact the doctors of the study and see if they clear this point.my guess is they mean response to chloroquine because it has a highrate of resistance
i was also confused about the 14%
so i dont understand how they can say this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB if only 14% responded to treatment.
how important was the methylene blue also.
i found a patent for it in the use of therapy for viral disease
you can read here
Methylene Blue Therapy of Viral Disease
http://www.google.com/patents/US20060264423
so i dont understand how they can say this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB if only 14% responded to treatment.
how important was the methylene blue also.
i found a patent for it in the use of therapy for viral disease
you can read here
Methylene Blue Therapy of Viral Disease
http://www.google.com/patents/US20060264423
if i get it correctly only 14.69% of 830 patients responded but to what?i guess to choloquine.
we have to define this to draw conclusions:
responded to treatment of malaria?
responded to treatment of both malaria and hbv?
artemisin/artesunate is by a great extent the most antimalaria drug with very little resistance if none in combo
http://www.ncbi.nlm.nih.gov/pubmed/16122816
Antiviral Res. 2005 Nov;68(2):75-83. Epub 2005 Aug 10.
Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.
Romero MR1, Efferth T, Serrano MA, Castaño B, Macias RI, Briz O, Marin JJ.
Author information
Abstract
The antiviral effect against hepatitis B virus (HBV) of artemisinin, its derivative artesunate and other compounds highly purified from traditional Chinese medicine remedies, were investigated. HBV production by permanently transfected HepG2 2.2.15 cells was determined by measuring the release of surface protein (HBsAg) and HBV-DNA after drug exposure (0.01-100 microM) for 21 days. The forms of HBV-DNA released were investigated by Southern-blotting. Neutral Red retention test was used to evaluate drug-induced toxicity on host cells. The compounds were classified according to their potential interest as follows: (i) none: they had no effect on viral production (daidzein, daidzin, isonardosinon, nardofuran, nardosinon, tetrahydronardosinon and quercetin); (ii) low: they were able to markedly reduce viral production, but also induced toxicity on host cells (berberine and tannic acid) or they had no toxic effect on host cells but only had a moderate ability to reduce viral production (curcumin, baicalein, baicalin, bufalin, diallyl disulphide, glycyrrhizic acid and puerarin); (iii) high: they induced strong inhibition of viral production at concentrations at which host cell viability was not affected (artemisinin and artesunate). Moreover, artesunate in conjunction with lamivudine had synergic anti-HBV effects, which warrants further evaluation of artemisinin/artesunate as antiviral agents against HBV infection.
we have to define this to draw conclusions:
responded to treatment of malaria?
responded to treatment of both malaria and hbv?
artemisin/artesunate is by a great extent the most antimalaria drug with very little resistance if none in combo
http://www.ncbi.nlm.nih.gov/pubmed/16122816
Antiviral Res. 2005 Nov;68(2):75-83. Epub 2005 Aug 10.
Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.
Romero MR1, Efferth T, Serrano MA, Castaño B, Macias RI, Briz O, Marin JJ.
Author information
Abstract
The antiviral effect against hepatitis B virus (HBV) of artemisinin, its derivative artesunate and other compounds highly purified from traditional Chinese medicine remedies, were investigated. HBV production by permanently transfected HepG2 2.2.15 cells was determined by measuring the release of surface protein (HBsAg) and HBV-DNA after drug exposure (0.01-100 microM) for 21 days. The forms of HBV-DNA released were investigated by Southern-blotting. Neutral Red retention test was used to evaluate drug-induced toxicity on host cells. The compounds were classified according to their potential interest as follows: (i) none: they had no effect on viral production (daidzein, daidzin, isonardosinon, nardofuran, nardosinon, tetrahydronardosinon and quercetin); (ii) low: they were able to markedly reduce viral production, but also induced toxicity on host cells (berberine and tannic acid) or they had no toxic effect on host cells but only had a moderate ability to reduce viral production (curcumin, baicalein, baicalin, bufalin, diallyl disulphide, glycyrrhizic acid and puerarin); (iii) high: they induced strong inhibition of viral production at concentrations at which host cell viability was not affected (artemisinin and artesunate). Moreover, artesunate in conjunction with lamivudine had synergic anti-HBV effects, which warrants further evaluation of artemisinin/artesunate as antiviral agents against HBV infection.
State
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
Research Journal of Pharmacy and Technology
Year : 2008, Volume : 1, Issue : 3
First page : ( 259) Last page : ( 259)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’ Patients for Their Carrier State
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
Research Journal of Pharmacy and Technology
Year : 2008, Volume : 1, Issue : 3
First page : ( 259) Last page : ( 259)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’ Patients for Their Carrier State
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
Research Journal of Pharmacy and Technology
Year : 2008, Volume : 1, Issue : 3
First page : ( 259) Last page : ( 259)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’ Patients for Their Carrier State
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
Research Journal of Pharmacy and Technology
Year : 2008, Volume : 1, Issue : 3
First page : ( 259) Last page : ( 259)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Follow-Up of Combination of Chloroquine with Anti-Viral Drugs Treated Chronic Hepatitis ‘B’ Patients for Their Carrier State
Jothivel Nandhakumar1,*, Singaravel Sengottuvelu1, Deivasigamani Karthikeyan1, Vasudevan Mani1, Sundaram Sureshkumar2, Sambasivam Narmadha2, Thangavel Sivakumar1
1Department of Pharmaceutics and Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, India-638052
2Department of Pharmacy Practice, KM College of Pharmacy, Madurai, Tamil Nadu, India-625107
*Corresponding Author E-mail: ***@****
Abstract
Anti-viral agents like interferon-alpha, lamivudine, ribavirin have a uncertain effect on chronic hepatitis B (CHB), when they were used alone. Chloroquine is a well known anti-malarial agent, apart from which is a lysosomotropic agent, was used along with intercalating agent like methylene blue and anti-viral agents to treat clinically confirmed CHB patients. The present study is aimed to check the efficacy of earlier treated CHB patients to know their different infection status i.e. whether they completely recovered or chronic carrier. A retrospective study was carried on Jun 1st 2001 to Feb 28th 2002 at a tertiary care liver speciality hospital located in south India. The previously enrolled viral hepatitis patient medication records (PMRs) had been perused, out of which 830 patients had taken the combinational drug (chloroquine, intercalating and anti-viral agents) treatment for CHB. These 830 patients were included for our study and called for clinical, biochemical investigations and follow-up. The responder's blood samples were collected to carryout virological profiles like HBsAg, anti-HBs, HBV DNA by PCR and anti-HCV, liver enzymes like SGPT and SGOT levels and lipid profiles like total cholesterol, triglycerides, HDL, LDL and VLDL. The follow-up report was compared with base line and end of trial (EOT). Out of 830 patients 122 (14.69%) responders were reported to hospital. Only 4 (3.3%) patients were showed HBsAg +ve in their serum and found to be –ve in HBV DNA by PCR. Both SGOT and SGPT levels significantly (P<0.001) increased at EOT and 87% of patients were got the anti-HBs level above 26 IU/L. So, this study reflects the given combination therapy was found to be effective to the extent of 100% cure of CHB.
Top
Keywords
Chloroquine, chronic hepatitis B, false carriers, HBV DNA.
CFS patients use artemisin as antiviral, it is a very good try combo with antivirals or pegintf
i beleive only chloroquine is a heavy drug
i beleive only chloroquine is a heavy drug
http://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=1&issue=3&article=030
sorry that is all i can find on this, but very interesting for sure, i am so tempted to try it
I also posted about some vitro studies about the malaria drugs like chloroquine and artesunate with the second more potent after a memeber told me his mother cleared hbv after malaria treatment
problems is artesunate, a widespectrum known antiviral, is not available in europe but it would be wise to try since sides should not be heavy
problems is artesunate, a widespectrum known antiviral, is not available in europe but it would be wise to try since sides should not be heavy
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
